Frazier Life Sciences Management L.P. Acquires 106,000 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Frazier Life Sciences Management L.P. lifted its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 22.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 583,327 shares of the company’s stock after purchasing an additional 106,000 shares during the period. Frazier Life Sciences Management L.P.’s holdings in Oruka Therapeutics were worth $11,311,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock worth $31,231,000 after purchasing an additional 1,572,853 shares during the period. Geode Capital Management LLC lifted its stake in shares of Oruka Therapeutics by 2,348.6% in the 4th quarter. Geode Capital Management LLC now owns 342,418 shares of the company’s stock worth $6,643,000 after purchasing an additional 328,434 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Oruka Therapeutics in the 4th quarter worth approximately $54,000. Wellington Management Group LLP lifted its stake in shares of Oruka Therapeutics by 15.8% in the 4th quarter. Wellington Management Group LLP now owns 95,089 shares of the company’s stock worth $1,844,000 after purchasing an additional 12,952 shares during the period. Finally, Barclays PLC bought a new position in shares of Oruka Therapeutics in the 4th quarter worth approximately $1,446,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Trading Up 3.0%

NASDAQ ORKA opened at $10.62 on Wednesday. Oruka Therapeutics, Inc. has a 12 month low of $5.49 and a 12 month high of $31.13. The company’s 50 day moving average is $9.83 and its two-hundred day moving average is $14.54. The stock has a market cap of $397.62 million, a price-to-earnings ratio of -1.70 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17. Sell-side analysts forecast that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ORKA. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research began coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 15th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of “Buy” and a consensus price target of $39.86.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.